ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY
Clinical trials for ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY trials appear
Sign up with your email to follow new studies for ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can we build a leukemia treatment in the hospital? new study aims to find out
Disease control Recruiting nowThis study is testing whether a special type of immune cell therapy (CAR-T cells) can be successfully made right at the hospital for children and adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The main goal is to see if…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY
Phase: NA • Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New CAR T-Cell therapy offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowThis study tests a new treatment for children and young adults (up to age 21) with a type of leukemia (CD19-positive) that has returned or not responded to standard therapy. The treatment uses specially engineered immune cells from a family donor to attack the cancer. The main go…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 04:10 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatment…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated May 26, 2026 03:58 UTC